These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 30765842)
21. G9a Inhibition Induces Autophagic Cell Death via AMPK/mTOR Pathway in Bladder Transitional Cell Carcinoma. Li F; Zeng J; Gao Y; Guan Z; Ma Z; Shi Q; Du C; Jia J; Xu S; Wang X; Chang L; He D; Guo P PLoS One; 2015; 10(9):e0138390. PubMed ID: 26397365 [TBL] [Abstract][Full Text] [Related]
22. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway. Ma W; Han C; Zhang J; Song K; Chen W; Kwon H; Wu T Hepatology; 2020 Oct; 72(4):1283-1297. PubMed ID: 31990985 [TBL] [Abstract][Full Text] [Related]
23. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer. Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression. Irifuku T; Doi S; Sasaki K; Doi T; Nakashima A; Ueno T; Yamada K; Arihiro K; Kohno N; Masaki T Kidney Int; 2016 Jan; 89(1):147-57. PubMed ID: 26444031 [TBL] [Abstract][Full Text] [Related]
25. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer. Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140 [TBL] [Abstract][Full Text] [Related]
26. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996 [TBL] [Abstract][Full Text] [Related]
27. Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and invasion by inhibiting G9a in non-small-cell lung cancer A549 cells. Zhang L; Liang B; Xu H; Gong Y; Hu W; Jin Z; Wu X; Chen X; Li M; Shi L; Shi Y; Wang Y; Yang L J Ethnopharmacol; 2022 Jun; 291():115095. PubMed ID: 35176466 [TBL] [Abstract][Full Text] [Related]
28. G9a promotes cell proliferation and suppresses autophagy in gastric cancer by directly activating mTOR. Yin C; Ke X; Zhang R; Hou J; Dong Z; Wang F; Zhang K; Zhong X; Yang L; Cui H FASEB J; 2019 Dec; 33(12):14036-14050. PubMed ID: 31647887 [TBL] [Abstract][Full Text] [Related]
29. BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells. Li Q; Wang L; Ji D; Bao X; Tan G; Liang X; Deng P; Pi H; Lu Y; Chen C; He M; Zhang L; Zhou Z; Yu Z; Deng A Invest New Drugs; 2021 Jun; 39(3):686-696. PubMed ID: 33387131 [TBL] [Abstract][Full Text] [Related]
30. [Inhibition of G9a attenuates cell proliferation via the mitochondrial apoptosis pathway in lung adenocarcinoma]. Wan HJ; Lyu W; Yu L; Zhou ZY; Hu YJ; Hu J Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):13-17. PubMed ID: 28104027 [No Abstract] [Full Text] [Related]
31. Targeting EHMT2/ G9a for cancer therapy: Progress and perspective. Jan S; Dar MI; Wani R; Sandey J; Mushtaq I; Lateef S; Syed SH Eur J Pharmacol; 2021 Feb; 893():173827. PubMed ID: 33347828 [TBL] [Abstract][Full Text] [Related]
32. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Vedadi M; Barsyte-Lovejoy D; Liu F; Rival-Gervier S; Allali-Hassani A; Labrie V; Wigle TJ; Dimaggio PA; Wasney GA; Siarheyeva A; Dong A; Tempel W; Wang SC; Chen X; Chau I; Mangano TJ; Huang XP; Simpson CD; Pattenden SG; Norris JL; Kireev DB; Tripathy A; Edwards A; Roth BL; Janzen WP; Garcia BA; Petronis A; Ellis J; Brown PJ; Frye SV; Arrowsmith CH; Jin J Nat Chem Biol; 2011 Jul; 7(8):566-74. PubMed ID: 21743462 [TBL] [Abstract][Full Text] [Related]
33. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374 [TBL] [Abstract][Full Text] [Related]
34. FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer. Chae YC; Kim JY; Park JW; Kim KB; Oh H; Lee KH; Seo SB Nucleic Acids Res; 2019 Feb; 47(4):1692-1705. PubMed ID: 30535125 [TBL] [Abstract][Full Text] [Related]
35. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents. Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells. Zhang J; Yao D; Jiang Y; Huang J; Yang S; Wang J Bioorg Chem; 2017 Jun; 72():168-181. PubMed ID: 28460359 [TBL] [Abstract][Full Text] [Related]
37. Essential Role of Histone Methyltransferase G9a in Rapid Tolerance to the Anxiolytic Effects of Ethanol. Berkel TDM; Zhang H; Teppen T; Sakharkar AJ; Pandey SC Int J Neuropsychopharmacol; 2019 Apr; 22(4):292-302. PubMed ID: 30590608 [TBL] [Abstract][Full Text] [Related]
38. G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Kelly GM; Al-Ejeh F; McCuaig R; Casciello F; Ahmad Kamal N; Ferguson B; Pritchard AL; Ali S; Silva IP; Wilmott JS; Long GV; Scolyer RA; Rao S; Hayward NK; Gannon F; Lee JS Clin Cancer Res; 2021 May; 27(9):2624-2635. PubMed ID: 33589432 [TBL] [Abstract][Full Text] [Related]
39. Radiation-induced H3K9 methylation on E-cadherin promoter mediated by ROS/Snail axis : Role of G9a signaling during lung epithelial-mesenchymal transition. Nagaraja SS; Subramanian U; Nagarajan D Toxicol In Vitro; 2021 Feb; 70():105037. PubMed ID: 33148527 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Segovia C; San José-Enériz E; Munera-Maravilla E; Martínez-Fernández M; Garate L; Miranda E; Vilas-Zornoza A; Lodewijk I; Rubio C; Segrelles C; Valcárcel LV; Rabal O; Casares N; Bernardini A; Suarez-Cabrera C; López-Calderón FF; Fortes P; Casado JA; Dueñas M; Villacampa F; Lasarte JJ; Guerrero-Ramos F; de Velasco G; Oyarzabal J; Castellano D; Agirre X; Prósper F; Paramio JM Nat Med; 2019 Jul; 25(7):1073-1081. PubMed ID: 31270502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]